TSOI Stock Analysis
TS
Uncovered
Therapeutic Solutions International Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Market cap $B
0.004
Dividend yield
—
Shares outstanding
2 656.58 B
Therapeutic Solutions International, Inc. engages in the manufacture of surgical and medical devices. The company is headquartered in Elk City, Idaho and currently employs 3 full-time employees. The company went IPO on 2008-06-09. The firm is engaged in developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, traumatic brain injury, lung pathologies, and for daily health. The company primarily produces nutraceuticals. Its lead product, QuadraMune, is a synergistic blend of pterostilbene, sulforaphane, epigallocatechin gallate, and thymoquinone. Its synergistic blend of ingredients helps the immune system fight off common and complex ailments and promotes healthy T-Cell activity. The firm also holds the rights to the development of adult stem cells for therapeutics in the areas of chronic traumatic encephalopathy (CTE) and traumatic brain injury (TBI) and lung pathology (LP). Its licensed stem cell, JadiCell, which possesses features of mesenchymal stem cells.